Dolutegravir use in combination with rifampicin-based tuberculosis therapy: 3 years of real-world experience in a large UK teaching hospital

Sex Transm Infect. 2018 Sep;94(6):420. doi: 10.1136/sextrans-2018-053698. Epub 2018 Jul 20.

Authors

Muge Cevik^{1

2}, Hugh McGann³

Affiliations

¹ Specialist Virology Centre, Royal Infirmary of Edinburgh, Edinburgh, UK.
² Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, UK.
³ Department of Infection and Travel Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

PMID: 30030303
DOI: 10.1136/sextrans-2018-053698

No abstract available

Keywords: HIV; antiretroviral therapy; audit; infectious diseases; tuberculosis.

Publication types

Letter

MeSH terms

Adult
Anti-HIV Agents / therapeutic use*
Drug Therapy, Combination
Female
HIV Infections / drug therapy*
Heterocyclic Compounds, 3-Ring / therapeutic use*
Hospitals, Teaching*
Humans
Male
Middle Aged
Oxazines
Piperazines
Pyridones
Rifampin / therapeutic use*
Treatment Outcome
Tuberculosis / drug therapy*
United Kingdom

Substances

Anti-HIV Agents
Heterocyclic Compounds, 3-Ring
Oxazines
Piperazines
Pyridones
dolutegravir
Rifampin